SCHEMBL740408

SCHEMBL740408

CN(C[C]=O)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 5/20 0.41
ADH1C P00326 3/20 0.41
HRH4 Q9H3N8 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ADH1B P00325 1/20 0.33
FDPS P14324 1/20 0.33
ABCB11 O95342 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
AR P10275 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7742694 1.00 ADH1A (0.41) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL4520995 0.98 HRH4 (0.38) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL22636064 0.88
SCHEMBL4973138 0.77 HRH4 (0.41) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL3954034 0.76 ADH1A (0.36) ADH1AADH1CALDH1A1ADH1BFDPS
SCHEMBL13296390 0.74 HRH3 (0.39) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL7535576 0.73 ADH1A (0.46) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL6039709 0.73 ADH1A (0.33) ADH1AADH1CALDH1A1FDPS
SCHEMBL15600812 0.73 HRH4 (0.37) ADH1AADH1CHRH4HRH3KDM4E
SCHEMBL7691331 0.72 HRH3 (0.48) ADH1AADH1CHRH4HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0833839-B1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMA CORP (US) 2003-01-08 EP claimed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-13 US disclosed
EP-1787982-B1 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS LLC (US) 2010-05-12 EP disclosed
US-7700583-B2 Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome HIGH POINT PHARMACEUTICALS, LLC (US) 2010-04-20 US disclosed
US-20090325932-A1 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS HIGH POINT PHARMACEUTICALS, LLC 2009-12-31 US disclosed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1878721-A1 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors NOVO NORDISK A/S (DK) 2008-01-16 EP disclosed
EP-1787982-A2 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds Novo Nordisk A/S (DK) 2007-05-23 EP disclosed
US-5574042-A ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN FUJISAWA PHARMACEUTICAL CO., LTD (JP) 1996-11-12 US disclosed
US-5563162-A CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-08 US disclosed
US-5484954-A HEATING, DEACYLATING NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1996-01-16 US disclosed
EP-0622361-A1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-02 EP disclosed
EP-0596406-A1 Imidazo (1,2-a) Pyridines as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-05-11 EP disclosed
US-5302730-A Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis NIPPON KAYAKU KK (JP) 1994-04-12 US disclosed
EP-0297496-B1 Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives NIPPON KAYAKU KK (JP) 1994-01-19 EP disclosed
US-5245052-A PROCESS FOR PRODUCING 6-ACYL-7-DEACETYLFORSKOLIN DERIVATIVES NIPPON KAYAKU CO. LTD. (JP) 1993-09-14 US disclosed
EP-0469428-A1 Novel process for producing 6-acyl-7-deacetylforskolin derivatives HOECHST JAPAN LIMITED (JP) 1992-02-05 EP disclosed
EP-0297496-A2 Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1989-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD3B1, HSD17B1 ADH1A 30/4885ADH1C 35/4885HRH4 2303/4885
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HSD11B1, HSD3B1, CES1 ADH1A 15/4885ADH1C 31/4885HRH4 256/4885
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 ADH1A 27/4885ADH1C 35/4885HRH4 2979/4885
US-20090325932-A1 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS HSD11B1, HSD3B1, HSD17B1 ADH1A 21/4885ADH1C 35/4885HRH4 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.